๐”– Bobbio Scriptorium
โœฆ   LIBER   โœฆ

Improving delivery of antineoplastic agents with anti-vascular endothelial growth factor therapy

โœ Scribed by Anthony D. Yang; Todd W. Bauer; E. Ramsay Camp; Ray Somcio; Wenbiao Liu; Fan Fan; Lee M. Ellis

Publisher
John Wiley and Sons
Year
2005
Tongue
English
Weight
279 KB
Volume
103
Category
Article
ISSN
0008-543X

No coin nor oath required. For personal study only.

๐Ÿ“œ SIMILAR VOLUMES

Co-delivery of anti-vascular endothelial
Co-delivery of anti-vascular endothelial growth factor siRNA and doxorubicin by multifunctional polymeric micelle for tumor growth suppression
โœ Hong-Yi Huang; Wei-Ti Kuo; Ming-Ju Chou; Yi-You Huang ๐Ÿ“‚ Article ๐Ÿ“… 2011 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 544 KB

## Abstract Nonviral gene carriers composed of biodegradable polymers or lipids have been considered as a safer alternative for gene carriers over viral vectors. We have developed multifunctional nanomicelles for both drug and gene delivery application. Polyethylenimine (PEI) was modified by grafti

Vascular endothelial growth factor is as
Vascular endothelial growth factor is associated with the efficacy of endocrine therapy in patients with advanced breast carcinoma
โœ Peggy Manders; Louk V. A. M. Beex; Vivianne C. G. Tjan-Heijnen; Paul N. Span; C. ๐Ÿ“‚ Article ๐Ÿ“… 2003 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 93 KB ๐Ÿ‘ 2 views

## Abstract ## BACKGROUND Vascular endothelial growth factor (VEGF) is a mediator of angiogenesis and is associated with a poor prognosis in patients with primary breast carcinoma. In the current study, the authors investigated whether there was an association between VEGF levels in tumor tissues

Vascular endothelial growth factor is as
Vascular endothelial growth factor is associated with the efficacy of endocrine therapy in patients with advanced breast carcinoma
โœ Kadri Altundag; Emin Tamer Elkiran; Ozden Altundag ๐Ÿ“‚ Article ๐Ÿ“… 2004 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 55 KB ๐Ÿ‘ 2 views

## Eighteen-Year Results in the Treatment of Early Breast Carcinoma with Mastectomy Versus Breast Conservation Therapy W e applaud the recent report by Poggi et al. 1 regarding the 18-year follow-up data of the National Cancer Institute randomized trial on breast conservation therapy (BCT) versus